In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions
about
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endotheliumBuprenorphine: a unique drug with complex pharmacologySystematic Review of Pharmacological Properties of the Oligodendrocyte LineageA double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphineComparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor systemAtipamezole reverses ketamine-dexmedetomidine anesthesia without altering the antinociceptive effects of butorphanol and buprenorphine in female C57BL/6J mice.The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone.In vivo activation of a mutant mu-opioid receptor by antagonist: future direction for opiate pain treatment paradigm that lacks undesirable side effects.Can ropinirole modulate reinforcing subjective effects of cocaine in humans?Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphineOligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancyBuprenorphine differentially alters opioid receptor adaptation in rat brain regions.Investigation of the antinociceptive activity of buprenorphine in sheep.Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.Assessment of an Orofacial Operant Pain Assay as a Preclinical Tool for Evaluating Analgesic Efficacy in RodentsNovel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.Transdermal buprenorphine in the treatment of chronic pain.A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependenceRoles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine.The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.Mu opioids and their receptors: evolution of a concept.Pain and u-shaped dose responses: occurrence, mechanisms, and clinical implications.Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine.Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine.A review of the studies using buprenorphine in cats.Reducing the harm of opioid overdose with the safe use of naloxone : a pharmacologic review.The present and future of opioid analgesics in small animal practice.Transdermal buprenorphine in chronic pain: indications and clinical experience.[High-dose buprenorphine for outpatient palliative pain therapy].Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants.Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups.Cardiorespiratory effects of four opioid-tranquilizer combinations in dogs.Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia.A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm.Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant.Peroperative buprenorphine: do high dosages shorten analgesia postoperatively?
P2860
Q24311749-EB3979C8-983C-4DC5-A436-E4F9BB631E5DQ24642980-9BA08E0D-0ED5-4D3D-99E1-C69B8F95031AQ26768210-FE1A5EF5-A579-496F-8A74-8F1F61A4981EQ30570686-DC9C79A6-B58D-4659-8E3C-0965C9A77218Q33837582-B3F1429D-81F3-4CCA-948D-7E9BF77F6D91Q34138291-B5691426-2811-4E74-8980-6E4F4FD0EF0FQ34561447-1AF120E9-57B1-49A1-AE66-D33E078C9F77Q34620052-5DEE0B37-82B8-4BD5-9A46-D5409E9C18E7Q34661770-D9439A65-768E-4280-877F-D7C021D5579FQ34763622-0AE0B9DF-525A-468B-8EC1-D0D946C22798Q35151904-BE1D09CC-A260-4EFF-920C-A15DF9E9345FQ35284997-F599B483-0E3A-42DB-AC57-583C8AAE77FBQ35552420-69B21AED-4AF0-4CC4-8987-A09994AAF804Q35653140-33A6BD94-DA7A-4A1A-84D3-81DB3B14BDAEQ35755099-E623CDC4-CCB9-4F06-9BD2-020DEF4E2CDAQ35863900-1D142537-020D-4F09-BCAC-9169161B13F7Q35906905-F1C7097B-80C9-4ECA-823C-489AE79FBAADQ36104010-9EAE717C-63C0-4BD6-8362-6A29A8D0A14DQ36153362-03EFD37F-03A7-46DE-A3A3-7B92B6788885Q36251877-DCA3EE55-C625-4ED8-8CDE-4AA784E30500Q36296864-B9AC5300-6A71-404E-B420-1D585DF2505FQ36838054-335F07A5-2C45-4C3E-8EE3-73B735775F0FQ37180966-83CF2615-5F1D-4F5C-AD19-8607E0702E3BQ37236111-EFBA3421-10C1-4D30-87E2-6D0F8AED2828Q37246019-253DF217-A67E-4FAB-8AD6-EA6401E51EF2Q37290396-4DB9412E-57C7-4853-A32B-85952D0F77B8Q37336685-1B94F94C-8487-4356-AEB1-A3264706C921Q38198132-0DE026B0-0963-44FF-94FF-CFD92C2CF3F3Q38417339-C34CFFDD-D79A-443B-94CB-A87DCECB90FDQ38789121-79492730-191C-4CA4-9211-65A809A0A677Q39312604-4C3C3C59-88D9-43E8-8F58-44776824C9F0Q40402726-17DB18D6-946D-408D-B618-5BFF5898610EQ41657869-88641F9E-6C74-4B14-999F-B66FEA7E1967Q43514245-8DAAAA61-001C-4460-A982-9ED86AFC5D2EQ44337909-AB332162-735B-4201-9717-B52B6CB43DA5Q44350300-E3FB0FFC-CEFD-436F-B69B-C955D9FBA343Q45412503-7EB32584-5C06-4E48-81DE-CBCF65193F3BQ48107130-26E65BF8-16B7-457C-91B7-0CDD55B6419DQ48497363-0F43DF6E-13FB-428E-AB73-2CE8829F0C76Q51801601-54551B56-322F-40B1-93A2-8B730BA1A14B
P2860
In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
In vivo receptor binding of th ...... istic and antagonistic actions
@en
In vivo receptor binding of th ...... stic and antagonistic actions.
@nl
type
label
In vivo receptor binding of th ...... istic and antagonistic actions
@en
In vivo receptor binding of th ...... stic and antagonistic actions.
@nl
prefLabel
In vivo receptor binding of th ...... istic and antagonistic actions
@en
In vivo receptor binding of th ...... stic and antagonistic actions.
@nl
P2860
P1476
In vivo receptor binding of th ...... istic and antagonistic actions
@en
P2860
P304
P356
10.1111/J.1476-5381.1981.TB10473.X
P407
P577
1981-11-01T00:00:00Z